Fil LTD Biogen Inc. Transaction History

Fil LTD

$96.6 Billion
Q1 2025

A detailed history of Fil LTD transactions in Biogen Inc. stock. As of the latest transaction made, Fil LTD holds 120,000 shares of BIIB stock, worth $15.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

120,000

Previous 104,717 14.59%

Holding current value

$15.6 Million

Previous $16 Million 2.54%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$133.43 - $153.27 $2.04 Million - $2.34 Million	15,283 Added 14.59%	120,000 $16.4 Million
Q4 2024 Feb 13, 2025	SELL	$146.47 - $191.55 $13.4 Million - $17.5 Million	-91,285 Reduced 46.57%	104,717 $16 Million
Q3 2024 Nov 13, 2024	SELL	$189.07 - $236.8 $112 Million - $141 Million	-594,603 Reduced 75.21%	196,002 $38 Million
Q2 2024 Aug 13, 2024	BUY	$190.52 - $236.72 $16.8 Million - $20.9 Million	88,193 Added 12.56%	790,605 $183 Million
Q1 2024 May 13, 2024	BUY	$212.02 - $267.71 $9.73 Million - $12.3 Million	45,910 Added 6.99%	702,412 $151 Million
Q4 2023 Feb 13, 2024	BUY	$222.59 - $267.94 $132 Million - $159 Million	593,158 Added 936.41%	656,502 $170 Million
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $162,618 - $183,541	-642 Reduced 1.0%	63,344 $16.3 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $27,249 - $31,487	99 Added 0.15%	63,986 $18.2 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $2.27 Million - $2.59 Million	8,864 Added 16.11%	63,887 $17.8 Million
Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $693,452 - $842,559	2,747 Added 5.25%	55,023 $15.2 Million
Q3 2022 Nov 10, 2022	BUY	$194.69 - $268.46 $10.2 Million - $14 Million	52,276 New	52,276 $14 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $12.8 Million - $15.2 Million	-68,291 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $847,743 - $1.07 Million	-4,375 Reduced 6.02%	68,291 $14.4 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $388,277 - $498,993	-1,734 Reduced 2.33%	72,666 $17.4 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $680,024 - $886,827	-2,403 Reduced 3.13%	74,400 $21.1 Million
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $4.41 Million - $7.06 Million	-17,034 Reduced 18.15%	76,803 $26.6 Million
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $3.44 Million - $4.03 Million	14,157 Added 17.77%	93,837 $26.3 Million
Q4 2020 Feb 08, 2021	BUY	$236.26 - $355.63 $18.6 Million - $27.9 Million	78,580 Added 7143.64%	79,680 $19.5 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $291,247 - $336,281	1,100 New	1,100 $312,000
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $9.78 Million - $12.9 Million	-37,802 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $447,635 - $567,831	1,665 Added 4.61%	37,802 $12 Million
Q4 2019 Feb 07, 2020	BUY	$220.06 - $304.07 $7.95 Million - $11 Million	36,137 New	36,137 $10.7 Million
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $43.8 Million - $68.5 Million	-201,969 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $286,298 - $362,627	1,028 Added 0.51%	201,969 $60.8 Million
Q3 2018 Nov 09, 2018	SELL	$293.51 - $383.83 $1.82 Million - $2.37 Million	-6,184 Reduced 2.99%	200,941 $71 Million
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $1.96 Million - $2.34 Million	7,612 Added 3.82%	207,125 $60.1 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $219,029 - $309,780	842 Added 0.42%	199,513 $54.6 Million
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $14.6 Million - $16.4 Million	-47,596 Reduced 19.33%	198,671 $63.3 Million
Q3 2017 Nov 13, 2017	SELL	$281.15 - $329.69 $8.96 Million - $10.5 Million	-31,862 Reduced 11.46%	246,267 $77.1 Million
Q2 2017 Aug 29, 2017	BUY	N/A	278,129	278,129 $75.5 Million

Others Institutions Holding BIIB

# of Institutions

1,026

Shares Held

127M

Call Options Held

2.29M

Put Options Held

4.26M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $18.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Account